DORVAL ALLISON sold 11.3% of their position (11.61K shares) of PUMA BIOTECHNOLOGY, INC. on the open market
Open‑market sale worth $83.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/16/2026ACC: 0001437749-26-020703
+15.39K
Net shares
Net buyer
$83.6K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
27K acquired · 11.61K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+27K
Price / share
—
Trade value
—
% of position
35.8%
6/11/2026
75.39K→102.39K
Common Stock
Direct
Shares
−11.61K
Price / share
$7.20
Trade value
$83.58K
% of position
11.3%
6/12/2026
102.39K→90.78K
Total
Net shares
+15.39K
Net value
-$83.58K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/11/2026 | A · Award | +27K | — | — | 35.8% | 75.39K | 102.39K |
| Common Stock Direct | 6/12/2026 | S · Sale | −11.61K | $7.20 | $83.58K | 11.3% | 102.39K | 90.78K |
| Total | +15.39K | -$83.58K | ||||||
Derivative Transactions0
No derivative transactions reported